Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acceptability of New Paediatric Hydroxycarbamide Formulation in Sickle Cell Disease
NCT05470270Phase 2Completed
- Sponsor
- Theravia
- Start
- Jul 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxyurea in sickle cell disease (SCD), sponsored by Theravia. Primary endpoint: Acceptability score at Day 1. Started Jul 2022; status: completed.
02
Drugs
hydroxyurea
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05470270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470270.